Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ADR ARGX

Healthcare Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an... see more

Recent & Breaking News (NDAQ:ARGX)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of argenx SE (ARGX)

Accesswire January 3, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

Accesswire January 3, 2024

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

Accesswire December 28, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

Accesswire December 26, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

Accesswire December 21, 2023

ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

Accesswire December 20, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

Newsfile December 20, 2023

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

GlobeNewswire December 20, 2023

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

GlobeNewswire November 28, 2023

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

GlobeNewswire November 16, 2023

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

GlobeNewswire November 1, 2023

argenx to Present at Upcoming Investor Conferences

GlobeNewswire November 1, 2023

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire October 31, 2023

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

GlobeNewswire October 24, 2023

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

GlobeNewswire September 21, 2023

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

GlobeNewswire September 15, 2023

argenx to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2023

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

GlobeNewswire July 27, 2023

argenx announces closing of global offering

GlobeNewswire July 24, 2023